ClinicalTrials.Veeva

Menu
B

Bradenton Research Center | Bradenton, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Bapineuzumab
YKP3089
Dazodalibep
Crenezumab
AVP-786
Gantenerumab
Rufinamide
Lyrica
Aducanumab
Donanemab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 72 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approxi...

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.

Enrolling
Sjögren's Syndrome
Drug: Dazodalibep

The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-s...

Enrolling
Chronic Low-back Pain
Diabetic Neuropathic Pain
Drug: LY3016859 ISA
Drug: Placebo Oral

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized...

Active, not recruiting
Myasthenia Gravis, Generalized
Drug: DNTH103
Drug: Placebo

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized...

Enrolling
Generalized Anxiety Disorder
Drug: MM120 (LSD D-Tartrate)
Other: Placebo

Primary Objective:To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom stateSecon...

Enrolling
Sjögren's Syndrome (SS)
Drug: Dazodalibep
Drug: Placebo

The primary objective of the study is to determine the dose response of E2814, when concurrently administered with lecanemab, on the change from base...

Active, not recruiting
Alzheimer's Disease
Drug: E2814
Drug: Lecanemab
Locations recently updated

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Drug: Lecanemab

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive a...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug

Primary Objective:To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe...

Enrolling
Sjogren's Syndrome
Drug: Dazodalibep
Drug: Placebo

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 ge...

Active, not recruiting
Early Alzheimer's Disease
Drug: Experimental: ALZ-801
Locations recently updated

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have particip...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Enrolling
Alzheimer Disease, Early Onset
Other: Placebo
Drug: BMS-986446

Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Re...

Enrolling
Multiple Sclerosis
Drug: IMU-838 tablets
Drug: Placebo matching IMU-838 tablets

Trial sponsors

Pfizer logo
Roche logo
Eisai logo
Lilly logo
Amgen logo
Genentech logo
Janssen (J&J Innovative Medicine) logo
Otsuka logo
SK Life Science logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems